Full Text View
Tabular View
No Study Results Posted
Related Studies
Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia
This study has been completed.
Study NCT00040105   Information provided by M.D. Anderson Cancer Center
First Received: June 19, 2002   Last Updated: May 28, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia, Myeloid, Chronic
Additional conditions recognized in this trial
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Leukemia, Myeloid, Chronic-Phase
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Myeloproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
Zarnestra (R115777)
Gleevec (Imatinib mesylate)
Additional drug interventions recognized in this trial
Imatinib
Tipifarnib
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
M.D. Anderson Cancer Center
Johnson &Johnson Pharmaceutical Research &Development, L.L.C.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services